Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11154055 | PMC |
| http://dx.doi.org/10.4269/ajtmh.24-0146 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ASAS recommendations on reporting axial spondyloarthritis clinical trials.
Ann Rheum Dis
September 2025
Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Objectives: This study aims to develop recommendations on reporting baseline features and outcomes from axial spondyloarthritis (axSpA) clinical trials based on the recently updated instrument set of the Assessment of SpondyloArthritis international Society (ASAS) core outcome set (COS).
Methods: A steering group (SG) convened a workgroup (WG), consisting of 13 ASAS members including rheumatologists, methodologists, epidemiologists, and 2 Young ASAS members. Recommendations on reporting axSpA trials baseline features and outcomes were developed in 3 steps: (1) the SG identified relevant baseline features from key axSpA clinical trials and formulated a proposal on how outcomes related to the instruments in the ASAS COS should be presented.
Neoadjuvant therapy of NSCLC: a review of the use and impact of monoclonal antibodies.
Expert Opin Biol Ther
September 2025
Division of Medical Oncology, "S.G. Moscati" Hospital, Avellino, Italy.
Introduction: From the 1960s and up until 2021, neoadjuvant chemotherapy has represented the standard of care for potentially resectable stage III (N2) Non-Small Cell Lung Cancer (NSCLC). However, in recent years, immunotherapy in the form of Immune Checkpoint Inhibitors (ICIs) has revolutionized oncology treatment strategies and several ICIs have been investigated for the neoadjuvant treatment of NSCLC, both in monotherapy and in combination with other ICIs or chemotherapy.
Areas Covered: Therefore, this paper aims to review the currently available data supporting the role of immunotherapy in the neoadjuvant setting, as well as to discuss the challenges associated with it.
Neural correlates of forward and backward walking in MS: insights from myelin water imaging.
Exp Brain Res
September 2025
Department of Health Care Sciences, Wayne State University, Eugene Applebaum College of Pharmacy and Health Care Sciences, 259 Mack Avenue, Detroit, MI, USA.
Mobility impairments and increased fall risk are common in multiple sclerosis (MS), resulting from myelin degradation in motor pathways. While forward walking is a common mobility assessment, backward walking shows greater sensitivity in distinguishing fallers due to its increased postural and cognitive demands. However, the neurobiological mechanisms underlying backward walking deficits remain unclear.
View Article and Find Full Text PDFInvestigating the Psychometric Properties of the Persian Version of the Revised Illness Perception Questionnaire in a Sample of Patients With Multiple Sclerosis.
Brain Behav
September 2025
Department of Clinical Psychology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Introduction: Illness perception significantly influences treatment adherence and quality of life among patients with multiple sclerosis (MS). Despite the widespread use of the Revised Illness Perception Questionnaire (IPQ-R) in different languages, a validated Persian version tailored for MS patients was lacking.
Methods: A cross-sectional study was conducted with 400 Persian-speaking MS patients recruited from the MS Society of Iran between December 2023 and April 2024.
Tumor-expressed GPNMB orchestrates Siglec-9 TAM polarization and EMT to promote metastasis in triple-negative breast cancer.
Proc Natl Acad Sci U S A
September 2025
Department of Experimental Pathology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
Metastasis remains the leading cause of cancer-related mortality, driven by complex interactions within the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) play a pivotal role in metastatic progression, yet their molecular diversity and upstream regulators remain poorly defined. Glycoprotein nonmetastatic melanoma protein B (GPNMB), overexpressed in subsets of tumors including triple-negative breast cancer (TNBC), is implicated in epithelial-mesenchymal transition (EMT) and cancer stemness.
View Article and Find Full Text PDF